Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2110183 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active Drug - GSK2110183 | EXPERIMENTAL | This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily. |
| Name | Type | Description |
|---|---|---|
| GSK2110183 | DRUG | GSK2110183 was orally administered at 125 mg once daily. |
Inclusion Criteria: 1. Written informed consent is provided. Adolescents will provide assent, with consent provided by parent or legal guardian. 2. Prior therapy restrictions: * Refractory/reactivation stratum: Age \>= 12 years of age at the time of study enrollment and Tanner Stage \>2. Subjec...
GSK2110183 is an investigational small molecule being studied for the treatment of Langerhans Cell Histiocytosis, a rare disease. It is currently in Phase 2 clinical development and has not been approved by the FDA.
GSK2110183 is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 2 clinical trials for Langerhans Cell Histiocytosis.
GSK2110183 is in Phase 2 clinical development. It is an investigational drug being studied for Langerhans Cell Histiocytosis and is not yet approved for any use.
GSK2110183 has one completed Phase 2 clinical trial, NCT01395004, which studied the drug in 17 patients with Langerhans Cell Histiocytosis in the United States. The trial was not randomized or double-blinded and had no control group.
GSK2110183 is the primary name for this investigational drug. No alternative names have been reported for this compound in the context of its clinical development for Langerhans Cell Histiocytosis.